Please join us in congratulating Maria Haley on her promotion to Senior Manager, Strategy & Insights at 81qd! Maria has made a tremendous impact on our organization, team and clients. Maria’s leadership, professionalism, and commitment to the MKG vision inspire her colleagues every day. We’re excited to see her take on new challenges and continue making a difference! #81qd #talenttuesday #Promotion #Leadership #StrategyAndInsights #Congratulations
关于我们
As an advanced healthcare data analytics company, 81qd provides customized and cost-effective solutions to life sciences organizations. Our name, 81qd, is derived from the smallest effective dosage of aspirin for preventing heart attack and stroke, and it exemplifies our mission of providing high-value, cost-effective solutions. Our team consists of data scientists, medical strategists, and marketing professionals, who have decades of experience in healthcare analytics. We leverage real-world data, artificial intelligence, and deep healthcare domain knowledge to accelerate disease diagnosis, drive product adoption, and maximize therapy adherence. Our core competencies include identifying and profiling key market stakeholders through data mining and disambiguation, mapping clinical networks and identifying clinical leaders, finding healthcare professionals managing yet-to-be-diagnosed and already diagnosed patients, developing proprietary tools to solve business problems on demand, and optimizing healthcare professional engagement. Our innovative techniques have allowed 8 of the top 10 pharma companies, as well as dozens of midsized and emerging biopharmaceutical companies to drive product adoption across a wide breadth of therapeutic areas. We take pride in our expertise and commitment to providing high-value solutions to help healthcare organizations maximize their commercial potential through all stages of product development and commercialization.
- 网站
-
https://www.81qd.com
81qd的外部链接
- 所属行业
- 数据基础架构与分析
- 规模
- 11-50 人
- 总部
- New York，New York
- 类型
- 私人持股
- 创立
- 2007
- 领域
- Social Network Analysis、KOL Profiling、KOL Validation、Network Mapping、US & Global Services、Objective KOL Assessment、Interaction Planning & Tracking、Pharmaceutical、Medical Devices、Biotechnology、Clinical Network Mapping、Patient Finding、KOL ID & Management、Stakeholder Management和Healthcare Data Mining
地点
-
主要
获取路线
285 Fulton Street
84th floor
US，New York，New York，10007
81qd员工
动态
-
What's next for pharma market research? Our affiliate company, Magnolia Innovation, has the answers. ?? Click below to dive deeper into the key takeaways: #81qd #MagnoliaInnovation #PMRC2025 #PharmaMarketResearch #AI #BehavioralResearch
Our team recently attended the Pharma Market Research Conference (PMRC) 2025, where they engaged with industry leaders to explore key insights on AI, behavioral research, and knowledge management. Dive deeper into the insights shaping the future of pharma market research: https://lnkd.in/g_YNv6Rb Ken Howie Jill (Salisbury) Arnese Alexandra Wilds Arun Sidhu John Capano, PhD #PharmaMarketResearch #MagnoliaInnovation #InsightsThatDriveAction #PMRC2025 #HealthcareStrategy #MKG
-
Fun + Productive Times in NYC with the 81qd Team! This week, we gathered our talented team for a two-day onsite meeting. It was a fantastic opportunity to bring everyone together in person, fostering collaboration and innovation through training, brainstorming sessions, and, of course, a slice of fun! One of the highlights? A pizza tour that took us through some of the best slices NYC has to offer, while providing us with a history lesson on pizza! ?? Not only did we enjoy delicious food, but we also strengthened our team bonds and shared many laughs along the way. Bringing our team together face-to-face allowed us to generate fresh ideas, and enhance our collective expertise. A huge thank you to everyone who contributed to making these two days a success by leading presentations and engaging in the sessions. #Team81qd #NYC #Innovation #TeamBuilding #Leadership #PizzaTour #WorkAndPlay
-
-
Join us in welcoming Alex Dixon to 81qd! We’re excited to have Alex on board as an Analyst. His analytical mindset and passion for healthcare strategy make him a great addition to our team. Welcome to 81qd, Alex—we look forward to your impact and growth with us! #WelcomeToTheTeam #81qd #HealthcareAnalytics #Biopharma #NewHire
-
-
How do we find the patients who need care the most, but haven’t been diagnosed yet? By using data-driven Patient-Finding Analytics to identify HCP practices where undiagnosed patients with rare or complex diseases are most likely to be. These insights, derived in partnership with our affiliate company, Magnolia Innovation, fuel everything from clinical trial enrollment to marketing strategy and patient access. Where do you see the biggest gaps in identifying undiagnosed patients? Learn more about our products and solutions: https://lnkd.in/gzJWDAat #RareDiseaseMonth #81qd #HealthcareInnovation #DataDrivenCare #patientfinding
-
-
81qd转发了
What does patient-focused drug development entail? For Alltrna CEO Michelle Werner, it means engaging with the rare disease community early and often. What does the patient journey look like? What are the real pain points in their lived experience with their disease, both as patients and as caregivers? What are they hoping for in therapies? As Michelle shares with Susan Asante-Abedi (Bentsi-Enchill) of 81qd, these families have knowledge that could be extraordinarily powerful for innovators working to bring the best medicines forward, faster. ???Listen to the full interview: https://lnkd.in/gChbm6Vx #RareAware #RareDiseaseWeek #RareDiseaseDay #RareDiseaseDay2025
-
Today is Rare Disease Day and we are excited to launch 81qd's podcast series "81qd Tools of Engagement" today on this important day for our team, our clients, and our communities. In this inaugural edition, Susan Asante-Abedi (Bentsi-Enchill) and Michelle Werner explore key opportunities for engaging stakeholders in the rare disease space. How can we drive more meaningful collaboration to improve patient outcomes? Topics include: ??? The most effective multi-disciplinary stakeholder engagement approaches for improving patient outcomes ??? How thought leader engagement in rare diseases differs from other conditions ??? Ways biopharma companies can gather insights from and build authentic partnerships with patient advocacy groups Our podcast series "81qd Tools of Engagement :The Science and Strategy of Stakeholder Engagement" is an interview-format podcast featuring diverse stakeholders sharing best practices for navigating the complexities of biopharma engagement. What strategies have you seen make the biggest impact in rare disease engagement? Share your thoughts below and tune in to the conversation. ?? Listen now: https://lnkd.in/gChbm6Vx #81qd #RareDiseaseDay #RareDiseaseAwareness
-
-
We’re thrilled to welcome Julianna Rabin to the 81qd team as our newest Analyst! We’re excited to have her on board and look forward to the impact she’ll make in optimizing our strategic approaches. #Welcome #NewTeamMember #81qd #HealthcareAnalytics #DataDriven
-
-
Managing a Speaker Bureau? The right combination of analytics and insights are key to success. With ASTOUND, you get a powerful tool that tracks performance, manages budgets, and ensures compliance all in one place. Request your demo today: https://lnkd.in/gPEdnygh #81qd #SpeakerBureau #DataAnalytics #PharmaTech #ASTOUND
-
-
Webinar Alert?? With the Trump administration reshaping DEI policies, the ripple effects on pharma could be profound. The big question: How will these changes impact health outcomes research, product value demonstration, and payer decision-making? Register for this timely discussion led by our affiliate Magnolia Market Access
?? How Will DEI Policy Shifts Impact Pharma, Med Device, and Payers? As the Trump Administration reshapes DEI policies, the long-term impact on healthcare access, product value, and payer decision-making remains uncertain. Life science companies now face critical questions: ?? How will life science companies demonstrate their products improve care for vulnerable populations and justify the value of bringing them to market to achieve payer coverage? ?? How can manufacturers gather valuable information to ensure appropriate clinical trial enrollment, valuable outcomes research, and patient access without strong DEI-driven data? ?? What do policy changes mean for the validity, collection, and use of RWE? Register here: https://lnkd.in/gjz4D7-v ?? Have a burning question? Submit it ahead of time to [email protected] #DEI #HealthEquity #RWE #MarketAccess
-